MACROGENICS, INC. (MGNX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 108.81M USD | Liabilities, Current |
| Cash and equivalents | 113.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 24.60M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $108.81M | $113.91M | (m) | $24.60M | (m) | (m) |
| 2026-03-31 | (m) | $95.94M | $66.52M | (m) | $10.43M | $9.50M | (m) |
| 2025-12-31 | (m) | $43.12M | $57.22M | (m) | $13.37M | $7.91M | (m) |
| 2025-09-30 | (m) | $44.47M | $80.13M | (m) | $69.23M | $8.75M | (m) |
| 2025-06-30 | (m) | $39.00M | $130.69M | (m) | $12.53M | $9.28M | (m) |
| 2025-03-31 | (m) | $55.44M | $145.57M | (m) | $10.54M | $9.43M | (m) |
| 2024-12-31 | (m) | $55.53M | $182.84M | (m) | $4.31M | $0.00 | (m) |
| 2024-09-30 | (m) | $59.31M | $179.63M | (m) | $8.75M | $3.24M | (m) |
| 2024-06-30 | (m) | $57.91M | $83.93M | (m) | $6.19M | $1.11M | (m) |
| 2024-03-31 | (m) | $55.76M | $80.36M | (m) | $7.22M | $1.25M | (m) |
| 2023-12-31 | (m) | $56.11M | $100.96M | (m) | $10.37M | $1.22M | (m) |
| 2023-09-30 | (m) | $51.29M | $89.90M | (m) | $25.31M | $1.07M | (m) |
| 2023-06-30 | (m) | $45.16M | $108.76M | (m) | $6.41M | $1.44M | (m) |
| 2023-03-31 | (m) | $45.61M | $224.26M | (m) | $36.16M | $1.41M | (m) |
| 2022-12-31 | (m) | $48.61M | $108.88M | (m) | $56.22M | $1.45M | (m) |
| 2022-09-30 | (m) | $50.05M | $83.99M | (m) | $13.84M | $1.09M | (m) |
| 2022-06-30 | (m) | $50.88M | $21.47M | (m) | $18.39M | $2.95M | (m) |
| 2022-03-31 | (m) | $67.10M | $47.33M | (m) | $14.90M | $4.60M | (m) |
| 2021-12-31 | (m) | $74.58M | $123.47M | (m) | $10.39M | $4.39M | (m) |
| 2021-09-30 | (m) | $68.86M | $190.53M | (m) | $13.76M | $3.98M | (m) |
| 2021-06-30 | (m) | $69.92M | $188.97M | (m) | $45.25M | $6.48M | (m) |
| 2021-03-31 | (m) | $53.04M | $218.50M | (m) | $7.15M | $6.17M | (m) |
| 2020-12-31 | (m) | $50.67M | $181.13M | (m) | $23.08M | (m) | (m) |
| 2020-09-30 | (m) | $50.12M | $201.64M | (m) | $18.78M | (m) | (m) |
| 2020-06-30 | (m) | $45.89M | $196.53M | (m) | $19.20M | (m) | (m) |
| 2020-03-31 | (m) | $39.61M | $93.06M | (m) | $11.81M | (m) | (m) |
| 2019-12-31 | $228.50M | $45.17M | $126.47M | $89.28M | $12.74M | (m) | 5.06× |
| 2019-09-30 | (m) | $57.63M | $156.59M | (m) | $9.50M | (m) | (m) |
| 2019-06-30 | (m) | $49.53M | $180.32M | (m) | $5.61M | (m) | (m) |
| 2019-03-31 | (m) | $51.77M | $238.64M | (m) | $6.12M | (m) | (m) |
| 2018-12-31 | $262.45M | $59.94M | $220.13M | $12.73M | $29.58M | (m) | 4.38× |
| 2018-09-30 | (m) | $48.02M | $201.81M | (m) | $20.97M | (m) | (m) |
| 2018-06-30 | (m) | $48.03M | $238.66M | (m) | $17.84M | (m) | (m) |
| 2018-03-31 | (m) | $49.96M | $200.45M | (m) | $7.28M | (m) | (m) |
| 2017-12-31 | $318.76M | $49.76M | $211.73M | $93.39M | $13.64M | (m) | 6.41× |
| 2017-09-30 | (m) | $32.44M | $90.88M | (m) | $2.19M | (m) | (m) |
| 2017-06-30 | (m) | $29.89M | $116.63M | (m) | $1.99M | (m) | (m) |
| 2017-03-31 | (m) | $26.55M | $40.52M | (m) | $2.09M | (m) | (m) |
| 2016-12-31 | $279.76M | $27.30M | $84.10M | $192.90M | $2.76M | (m) | 10.25× |
| 2016-09-30 | (m) | $22.05M | $109.90M | (m) | $3.01M | (m) | (m) |
| 2016-06-30 | (m) | $19.53M | $62.27M | (m) | $78.38M | (m) | (m) |
| 2016-03-31 | (m) | $17.81M | $151.95M | (m) | $2.51M | (m) | (m) |
| 2015-12-31 | (m) | $23.29M | $196.17M | (m) | $1.22M | (m) | (m) |
| 2015-09-30 | (m) | $22.39M | $365.77M | (m) | $2.74M | (m) | (m) |
| 2015-06-30 | (m) | $23.85M | $235.03M | (m) | $4.33M | (m) | (m) |
| 2015-03-31 | (m) | $24.13M | $263.13M | (m) | $1.72M | (m) | (m) |
| 2014-12-31 | (m) | $27.09M | $157.59M | (m) | $2.94M | (m) | (m) |
| 2014-09-30 | (m) | $25.99M | $179.19M | (m) | $5.32M | (m) | (m) |
| 2014-06-30 | (m) | $29.87M | $194.01M | (m) | $2.65M | (m) | (m) |
| 2014-03-31 | (m) | $29.38M | $198.72M | (m) | $1.75M | (m) | (m) |
| 2013-12-31 | (m) | $28.82M | $116.48M | (m) | $2.00M | (m) | (m) |
| 2013-09-30 | (m) | $25.27M | $33.57M | (m) | $2.28M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $33.78M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $43.53M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $29.73M | $47.74M | (m) | $2.05M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $30.45M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $55.22M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $36.88M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |